

Contents

1	Introduction –	
	Positron Emission Tomography: Past and Present	1
1.1	Survey	1
	Physical and Biochemical Fundamentals	2
	PET in National and International Medical Care Systems	2
1.2	Technological Variants and Developments	4
	Coincidence PET vs. Dedicated PET	4
	Differentiated PET Evaluation	4
	Radiotherapeutic Tools	5
	PET/CT – a New Key Technology	5
	Influence of PET/CT on PET	5
	Studies Dealing with the Cost Efficiency of PET Alone	6
	PET/CT or Comparison of Co-Registered Findings?	6
	“Standard” (CARE)-CT and PET/CT	6
	PET/MRI?	6
	American Joint Committee on Cancer	7
	PET Screening in Japan and Taiwan	7
1.3	Increased FDG Uptake Due to Physiological and Technical Factors	7
1.4	References	8
2	Fundamentals	
	THOMAS BEYER	11
2.1	Preface	11
	Positron Emission Tomography (PET)	11
	Radioisotopes and PET Tracers	12
	Coincidence Measurement and Quantification	13
	PET Measurement Results and Reconstruction	14
	PET Scanners and Scintillation Detectors	16
2.2	Combined PET/CT	18
	Retrospective Image Fusion	18
	The PET/CT Prototype	18
	CT-Based Attenuation Correction	20
	Commercialization of PET/CT	21
	New Technical Developments in PET/CT	23
	PET/CT Acquisition Protocols	29
	Sources of Errors and Optimization Options	30
	Radiation Protection Aspects	37
2.3	Conclusion	40
2.4	References	40
3	Pneumology	43
3.1	Bronchial Carcinoma (BC)	43
3.2	Significance of FDG-PET in Diagnostic and Therapeutic Management	44
	Critical Evaluation of Diagnosis Management	45
3.3	Guidelines for ¹⁸ F-FDG-PET Indications	45
3.4	Technical and Biochemical Factors	46
	Is Coincidence PET Equivalent to Full-Ring PET?	46
	PET as Metabolism and Proliferation Marker	46
	Innovative Radiopharmacy	46
3.5	Special PET Indications	47
	False-Negative PET	47
	False-Positive PET	47
	How Useful Is Integrated PET/CT?	48
3.6	SCLC (Small-Cell Lung Cancer)	48
3.7	Pleural Processes	48
	Malignant Pleural Tumours (Mesothelioma)	49
	Imaging Methods	49
3.8	Case Studies	50
	Patient 1 Scar Carcinoma of the Lung	50
	Patient 2 Pneumonia	52
	Patient 3 Lymph Node Metastases of a Squamous Cell Carcinoma	54
	Patient 4 Metastasized Bronchial Carcinoma	56
	Patient 5 Round Focus in the Lung	58
	Patient 6 Metastasized Bronchial Carcinoma	60
	Patient 7 Metastasized Adenocarcinoma in the Left Lower Lobe of the Lung	61
	Patient 8 Downstaging of a Squamous Cell Carcinoma of the Lung	62
	Patient 9 Preoperative Staging of a Bronchial Carcinoma	64
	Patient 10 Pleural Carcinosis after Pneumectomy	66
	Patient 11 Recurrence of a Brain Metastasis	69
	Patient 12 Pleural Mesothelioma	71
	Patient 13 Prevention of Non-Curative Thoracic Surgery	73
	Patient 14 Upstaging of a Bronchial Carcinoma	76
	Patient 15 Bilateral Metastases of an NSCLC in the Suprarenal Glands	79
3.9	References	82

4 Gastroenterology	85	Patient 7	Hepatocellular Carcinoma with Multiple Metastases	114
4.1 Introduction	86	Patient 8	Gastric Carcinoma	117
Molecular Strategy	87	Patient 9	Leiomyoma of the Stomach	118
Metabolic Influencing Factors	88	Patient 10	Follow-Up of an Adenocarcinoma of the Stomach	121
PET Screening?	88	Patient 11	Staging of an Adenocarcinoma of the Stomach	123
Incidentally Detected Lesions (IDL)	88	Patient 12	Staging of a Carcinoma of the Corpus of the Stomach	124
4.2 Oesophageal Carcinoma	88	Patient 13	Lymph Node Metastasis from Gastric Carcinoma	126
PET in Diagnosis Management of Oesophageal Carcinoma	88	Patient 14	Extended Metastatic Spread to the Liver from Adenocarcinoma of the Stomach	128
4.3 Gastric Carcinoma	90	Patient 15	Caecum Carcinoma	130
MALT Lymphomas	90	Patient 16	Carcinoma of the Colon Ascendens	132
4.4 Colorectal Carcinomas	90	Patient 17	T1 Carcinoma of the Colon	134
Treatment	91	Patient 18	Adenocarcinoma of the Sigmoid Colon	136
Status of PET	91	Patient 19	Liver Metastasis of a Colon Carcinoma	138
PET/CT as the Optimum	93	Patient 20	Lymphoma Conglomerate Following Colon Carcinoma	140
PET Indications	93	Patient 21	Lung Metastasis Following Colon Carcinoma	142
Limitations of PET	94	Patient 22	Pulmonary, Hepatic and Lymphogenic Metastatic Spread Following Sigmoid Carcinoma	144
Artefacts	94	Patient 23	Metastasized Sigmoid Carcinoma	146
FDG-PET	94	Patient 24	Peritoneal Carcinosis and Ascites Following Sigmoid Carcinoma	148
Alternative and Adjuvant Markers	94	Patient 25	Lung Metastasis Following Sigmoid Carcinoma	150
Synopsis	95	Patient 26	Liver Metastasis Following Sigmoid Carcinoma	153
4.5 Liver and Biliary Tract Carcinomas	95	Patient 27	Lymph Node Metastasis Following Sigmoid Carcinoma	156
4.6 Gastrointestinal Stromal Tumours	95	Patient 28	Metastatic Spread to the Liver Following Rectal Carcinoma	158
4.7 Pancreas Carcinomas	96	Patient 29	Liver and Lung Metastases Following Rectal Carcinoma	160
Imaging	96	Patient 30	Rectal Carcinoma with Lymph Node Metastases	163
Curative Treatment	97	Patient 31	Suprarenal and Lung Metastases Following Rectal Carcinoma	166
New Gene-Based Treatment Strategies	97	Patient 32	Lung and Bone Metastases Following Rectal Carcinoma	168
Indications	97	Patient 33	Suprarenal Metastasis of a Rectal Carcinoma	169
DGN Classes, Consequences	97	Patient 34	Restaging of a Rectal Carcinoma	172
Impact of SUVs on Survival Time	97	Patient 35	Suprarenal and Lung Metastases Associated with Rectal Carcinoma	174
False-Negative/-Positive PET Findings	97	Patient 36	Restaging of a Rectal Carcinoma	176
Pancreas NETs (Neuroendocrine Tumours)	98	Patient 37	Local Recurrence and Liver Metastases of a Rectal Carcinoma	178
4.8 Neuroendocrine Tumours (NETs) of the Gastrointestinal Tract	98	Patient 38	Extended Metastatic Spread of a Mesenteric Conglomerate Tumour	181
Carcinoids	98	Patient 39	GIST Tumour with Liver Involvement	183
Conventional Diagnostics	98	Patient 40	Malignoma in the Left Epigastric Region	184
NET Spectrum	99			
Biochemistry	99			
High Secretors	99			
Low (Non-)Secretors	99			
Limitations of PET	99			
4.9 Case Studies	100			
Patient 1 Oesophageal Carcinoma	100			
Patient 2 Lymph Node Metastasis of an Oesophageal Carcinoma	103			
Patient 3 Downstaging of an Oesophageal Carcinoma	105			
Patient 4 Carcinoma of the Head of the Pancreas	107			
Patient 5 Metastasized Carcinoma of the Head of the Pancreas	110			
Patient 6 Carcinoma of the Body of the Pancreas	112			

Patient 41	GIST, Metastasis at the Greater Curvature of the Stomach . . .	186	Patient 5	Restaging of a Breast Cancer	224
Patient 42	Tumour Recurrence with Status Post GIST of the Stomach . . .	187	Patient 6	Restaging of a Breast Cancer	226
Patient 43	Therapy Response Follow-Up Examination Post GIST Resection . .	189	Patient 7	Confirmation of the Diagnosis "Breast Cancer"	228
Patient 44	Therapy Follow-Up in the Case of GIST	193	Patient 8	Psammoma	230
4.10	References	200	Patient 9	Ovarian Cancer	232
5	Gynaecology	205	Patient 10	Restaging of an Ovarian Cancer . . .	234
5.1	Introduction	206	Patient 11	Therapy Response of a Metastasized Ovarian Cancer	236
	The Importance of Nuclear Medical Methods	206	Patient 12	Metastasized Cervical Cancer	238
5.2	Breast Cancers	206	Patient 13	Bone Metastasis of a Corpus Uteri Cancer	240
	Mammography	207	Patient 14	Trophoblastic Tumour	242
	Tumour Markers	208	Patient 15	Malignant Ovarian Cyst	244
	CT and MRI	208	Patient 16	Peritoneal Carcinosis Due to Ovarian Cancer	245
	¹⁸ F-Fluoride	209	Patient 17	Metastasized Endometrial Carcinoma	248
	SPECT	209	Patient 18	Exclusion of Metastatic Spread of an Endometrial Carcinoma	250
	Sentinel Node Scintigraphy (SNS)	209	Patient 19	Therapy Control in Case of Ovarian Carcinoma	252
	Positron Emission Tomography	209	Patient 20	Lymph Node and Bone Metastases in Case of Ovarian Carcinoma	254
	Preoperative Axillary Staging	210	Patient 21	Local Recurrence of Breast Cancer .	256
	Extra-Axillary Metastases	211	Patient 22	Restaging of a Breast Cancer after Chemotherapy	259
	Treatment Monitoring	211	Patient 23	Restaging of a Breast Cancer after Rise in Tumour Marker Level	261
	Potentials and Limitations of PET	211	Patient 24	Primary Staging of a Breast Cancer .	262
	Special Neuro-Oncological Problems/Pitfalls . .	212	Patient 25	Restaging of a Breast Cancer after Reduction in Tumour Marker Level .	264
	PET Screening?	212	Patient 26	Pre-Therapeutic Staging of a Breast Cancer	267
	Risk Stratification	212	Patient 27	Restaging of a Metastasized Breast Cancer	269
	PET/CT	212	Patient 28	Detection of Metastases by PET/CT with Negative Conventional Imaging	271
	Assessment of the Bone Status	212	Patient 29	Therapy Control of a Metastasized Breast Cancer	275
	¹⁸ F-Fluoride PET	212	Patient 30	Therapy Control of a Metastasized Breast Cancer	276
	Diagnostic Imaging of the Breast: Indications .	212	Patient 31	Evaluation of Radiotherapy Response in Case of Metastasized Breast Cancer	279
5.3	Ovarian Cancer	213	Patient 32	Restaging of a Breast Cancer	283
	Tumour Types	213	Patient 33	Restaging of a Breast Cancer Revealing a Fracture Risk in the C6 Vertebral Body	285
	Conventional Diagnostics	213	Patient 34	Restaging of a Breast Cancer with PET/CT Providing Much More Detailed Information	287
	PET	213	Patient 35	Pleural Carcinosis in a Patient with Breast Cancer	290
5.4	Peritoneal Cancer (PC)	215	Patient 36	Lung Metastases of a Breast Cancer .	292
5.5	Cervical Cancer	215	Patient 37	Bone Metastases of a Breast Cancer .	294
	PET Diagnostics	215	Patient 38	Male Patient with Metastasized Breast Cancer	296
5.6	Case Studies	216	5.7	References	298
	Patient 1	Lymph Node Metastasis with Status Post Carcinoma of the Right Breast and Ovarian Carcinoma on Both Sides	216		
	Patient 2	Inflammatory Breast Cancer	218		
	Patient 3	Breast Cancer with Osseous Metastases	220		
	Patient 4	Preoperative Staging of a Breast Cancer	222		

6 Urology	303	Patient 26 First Diagnosis of a Prostate Carcinoma	361
6.1 Introduction	303	Patient 27 Response Evaluation of a Prostate Carcinoma	362
6.2 Renal Malignancies	304	6.9 References	363
Introduction	304		
Diagnostics	304		
6.3 Adrenal Tumours	305	7 Head and Neck Region	369
Imaging Diagnostics	305	7.1 Head and Neck Tumours	369
6.4 Bladder Carcinoma	305	¹⁸ F-FDG-PET	371
Status of PET	306	FDG-PET Pitfalls	373
6.5 Prostate Carcinoma	306	PET Indications	373
Introduction	306	7.2 Thyroid Carcinomas	374
Diagnostics	306	¹⁸ F-FDG-PET	375
Treatment	309	7.3 Case Studies	378
Status of Individual Imaging Methods	309	Patient 1 CUP Tumour	378
6.6 Germ Cell Tumours	313	Patient 2 Tumour Recurrence of an Atypical Laryngeal Carcinoid	380
Introduction	313	Patient 3 Restaging of an Oropharyngeal Carcinoma	381
PET Study Situation	314	Patient 4 Hypopharyngeal Carcinoma	384
6.7 Penis Carcinoma	315	Patient 5 Restaging after Multiple Carcinoma	386
6.8 Case Studies	316	Patient 6 Auricle Carcinoma	388
Patient 1 Malignoma of the Base of the Bladder	316	Patient 7 Tonsillar and Laryngeal Carcinoma and Carcinoma of the Base of the Tongue	390
Patient 2 Malignoma of the Posterior Wall of the Bladder	318	Patient 8 Recurrence of a Squamous Cell Carcinoma of the Tongue	392
Patient 3 Metastasis in the Suprarenal Gland on the Left Side	320	Patient 9 Tonsillar Carcinoma	394
Patient 4 Metastasis in the Suprarenal Gland on the Right Side	322	Patient 10 Restaging of a Small-Cell Carcinoma of the Left Principal Nasal Cavity	396
Patient 5 Metastasized Renal Cell Carcinoma	325	Patient 11 Recurrence of a Vocal Cord Carcinoma	400
Patient 6 Restaging after Chemotherapy	327	Patient 12 Cerebral Metastatic Spread of a Bronchial Carcinoma	402
Patient 7 Restaging after Tumour Nephrectomy	330	Patient 13 Cystadenocarcinoma of the Lacrimal Sac	405
Patient 8 Recurrence after Tumour Nephrectomy	332	Patient 14 Alzheimer's Disease	406
Patient 9 Metastasized Prostate Carcinoma	334	Patient 15 Oligodendroglioma on the Left Side	408
Patient 10 Metastasized Prostate Carcinoma	336	Patient 16 Low-Malignancy Brain Tumour on the Left Side	410
Patient 11 Restaging of a Prostate Carcinoma	338	Patient 17 Hypophyseal Metastasis	413
Patient 12 Lymph Node Metastasis of a Prostate Carcinoma	340	7.4 References	415
Patient 13 First Diagnosis of a Prostate Carcinoma	342		
Patient 14 Restaging of a Prostate Carcinoma	343	8 Dermatology	419
Patient 15 Restaging of a Prostate Carcinoma	345	8.1 Malignant Melanoma (MM)	419
Patient 16 Therapy Control for Metastasized Prostate Carcinoma	347	Introduction	419
Patient 17 Staging of a Prostate Carcinoma	349	Significance of PET	421
Patient 18 Local Recurrence of a Prostate Carcinoma	351	Pitfalls	421
Patient 19 Lymph Node Metastasis of a Prostate Carcinoma	352	PET Indications	421
Patient 20 Lymph Node Metastases of a Prostate Carcinoma	353	8.2 Case Studies	422
Patient 21 First Diagnosis of a Prostate Carcinoma	354	Patient 1 Malignant Melanoma of the Right Thigh	422
Patient 22 Prostatitis	355	Patient 2 Recurrent Melanoma	424
Patient 23 Prostatitis	356		
Patient 24 Prostatitis	357		
Patient 25 Restaging of a Prostate Carcinoma	359		

Patient 3	Metastasized Melanoma	426
Patient 4	Choroidal Melanoma	427
Patient 5	Metastasized Amelanotic Melanoma	428
8.3	References	433

9 Lymphomas 435

9.1	Introduction	435
9.2	Diagnosis	436
	Imaging Methods	436
	FDG-PET	437
	Response Evaluation	437
	Comparison of FDG-PET, ⁶⁷ Ga and CT	438
	Autologous Stem Cell Therapy	438
	PET/CT Restaging	438
	Artefacts	439
	Other Problems	439
	PET Indications	439

9.3 Case Studies 440

Patient 1	Follicular Non-Hodgkin's Lymphoma	440
Patient 2	Metastasized Non-Hodgkin's Lymphoma	442
Patient 3	B-Cell Lymphoma in the Hypopharynx	444
Patient 4	B-Cell Lymphoma	446
Patient 5	Lymphogranulomatosis, Nodular Sclerosis	448
Patient 6	T-Cell Lymphoma of the Cervical Lymph Tract	449
Patient 7	B-Cell Lymphoma	451
Patient 8	Restaging of Hodgkin's Disease	454
Patient 9	Recurrent Hodgkin's Lymphomas	459
Patient 10	Chronic Lymphatic Leukaemia	461
Patient 11	Restaging of the Multiple Myeloma	461

9.4 References 463

10 Oncological Orthopaedics 465

10.1	Introduction	465
10.2	Significance of PET	465
	PET Tracers	466
	PET Indications	466

10.3 Case Studies 467

Patient 1	Sweat Gland Carcinoma	467
Patient 2	Haemangioendothelioma	470
Patient 3	Chondrosarcoma	473
Patient 4	Medullary Osteosarcoma	476
Patient 5	Clear Cell Sarcoma	478
Patient 6	Rhabdomyosarcoma	480
Patient 7	Rhabdomyosarcoma of the Left Thigh	482
Patient 8	Embryonal Rhabdomyosarcoma	484

10.4 References 486

11 Paediatric Oncology 487

11.1	Introduction	487
	Changes in the Range of Clinical Indications	488

11.2	Lymphomas in Childhood	488
	Staging, Restaging, Prognosis and Therapy Control	488

11.3	Oncological Orthopaedics in Childhood	488
------	---------------------------------------	-----

11.4	Neuroblastomas	488
------	----------------	-----

11.5	Malignant Melanomas	488
------	---------------------	-----

11.6	Nesidioblastosis (Congenital Hyperinsulinism)	489
------	---	-----

11.7 Case Studies 490

Patient 1	Status Post Osteogenous Sarcoma	490
Patient 2	Status Post Mastitis	491
Patient 3	Embryonal Rhabdomyosarcoma	492
Patient 4	Focal Congenital Hyperinsulinism	494
Patient 5	Focal Congenital Hyperinsulinism	496
Patient 6	Focal Congenital Hyperinsulinism	498
Patient 7	Diffuse Congenital Hyperinsulinism	500
Patient 8	Focal Congenital Hyperinsulinism	502
Patient 9	Focal Congenital Hyperinsulinism	504
Patient 10	Focal Congenital Hyperinsulinism	506
Patient 11	Langerhans Cell Histiocytosis	508
Patient 12	Langerhans Cell Histiocytosis, Staging and Restaging	510

11.8 References 514

12 CUP Tumours 515 (Cancer of Unknown Primary)

12.1	Introduction	515
------	--------------	-----

12.2	Significance of PET	516
	Cancer of Unknown Primary:	
	Indication for PET/CT?	516
	Studies Available	516
	Artefacts, Pitfalls and Metabolic Heterogeneity	516

12.3 Case Studies 517

Patient 1	Carcinoma of the Base of the Tongue	517
Patient 2	Carcinoma of the Base of the Tongue	518
Patient 3	Oropharyngeal Carcinoma	520
Patient 4	Cholangiocarcinoma	523
Patient 5	Pancreatic Carcinoma	526
Patient 6	Carcinoma of the Head of the Pancreas	528
Patient 7	Mamma Carcinoma	530
Patient 8	CUP Tumour	533
Patient 9	Mamma Carcinoma	536
Patient 10	Carcinoma of the Base of the Tongue	538
Patient 11	Bronchial Carcinoma	540
Patient 12	Bronchial Carcinoma	542

12.4 References 544

13 Pitfalls	545	14 Radiotherapeutic Aspects	625
13.1 Testicular Carcinoma and Other Primary Tumours	546	14.1 Introduction	625
Universal Organ Spectrum of SPT	546	14.2 PET-Assisted Radiotherapy Planning	625
13.2 Physiological Accumulation of FDG	547	14.3 Advantages of PET/CT Integration	626
13.3 False Positive FDG Accumulations in the Oncological Sense	547	14.4 Fundamentals Governing the Use of PET/CT Data for Radiotherapy – Bits and Bytes and DICOM . . .	626
13.4 Artefacts Due to Technical Factors	547	14.5 Case Studies	630
13.5 False Negative PET Findings	547	Patient 1 Prostate Cancer	630
13.6 Case Studies Secondary Tumours	548	Patient 2 Oropharyngeal Cancer	632
Patient 1 Inflammatory Carcinoma of the Breast and Papillary Carcinoma of the Inner Genital Tract	548	Patient 3 Breast Cancer	634
Patient 2 Carcinoma in Situ with Osteoplastic Metastases 10 years later	551	Patient 4 Prostate Cancer	636
Patient 3 Recurrence of a Sigmoid Carcinoma, Compression of the Left Ureter	554	Patient 5 Squamous Cell Carcinoma of the Oral Cavity	638
Patient 4 Cervical Carcinoma and Rectal Carcinoma	556	Patient 6 Bronchial Cancer	640
Patient 5 Mamma Carcinoma and Colon Carcinoma	558	14.6 References	643
Patient 6 Mamma Carcinoma and Sigmoid Carcinoma	560	15 Nuclear Cardiology	645
Patient 7 Thymoma	561	– the Situation in Europe	
Patient 8 Prostate Carcinoma and Colon Carcinoma	564	15.1 Introduction	645
Patient 9 Renal Cell and Prostate Carcinoma	566	Development of Nuclear Cardiology and the Present State	645
Patient 10 Prostate Carcinoma and Colon Carcinoma	568	Molecular Cardiac Imaging	647
Patient 11 Carcinoma in Situ of the Rectum and Bronchial Carcinoma	570	Fusion Imaging	649
Patient 12 Non-Hodgkin's Lymphoma and Bronchial Carcinoma	574	SPECT and SPECT/CT	650
Patient 13 Mamma Carcinoma and Bronchial Carcinoma	577	MRI and PET/MRI	652
Patient 14 Coecum, Bronchial and Renal Carcinoma	579	15.2 Cardiac PET/CT	652
Patient 15 Mamma, Cervical and Rectal Carcinoma	583	Coronary Sclerosis	652
Patient 16 Parotid and Colon Carcinoma	586	Diabetes Mellitus and Coronary Sclerosis	654
13.7 Case Studies		Plaque Imaging	655
Physiologically Increased Uptake	589	Perfusion	656
Patient 17–21	589	Vitality	657
13.8 Case Studies		Radiation Exposure and Contrast Medium Safety	657
Non-Oncological Increased Uptake of Inflammatory Genesis	593	Artefacts	658
Patient 22–31	593	Invasive Diagnostics, Treatment and Treatment Monitoring	658
13.9 Case Studies		Prevention	661
Artefacts	611	Remarks on the Catalogue for Further Training for the Specialization in Nuclear Medicine	661
Patient 32–39	611	15.3 Case Studies	663
13.10 References	622	Patient 1 Mild CHD	663
		Patient 2 Status Post Revascularization	666
		Patient 3 Status Post Anterior Infarction and Sextuple Bypass	668
		Patient 4 Surprise Finding of Stem Stenosis	672
		15.4 Reference	676

16 Cardiac PET and PET/CT	687	16.4 Vascular Inflammation and Atherosclerosis . .	709
– the Situation in the USA		16.4.1 Large Vessel Vasculitis	709
16.1 Introduction	687	16.4.2 Atherosclerosis and Plaque Imaging	711
16.2 Coronary Artery Disease	687	16.5 Future Developments	714
Imaging with PET	688	16.6 References	714
Accuracy of PET and PET/CT Stress-Rest			
Myocardial Perfusion Imaging	693		
Advantages of Myocardial Perfusion Imaging			
with PET.	696		
Hybrid PET/CT Myocardial Perfusion Imaging			
in Coronary Artery Disease	697		
16.3 Myocardial Viability	698		
Concepts and Pathophysiology	699		
Assessment of Myocardial Viability	699		
Imaging of Myocardial Perfusion			
and Metabolism	701		
Clinical Implications of			
Perfusion Metabolism Imaging	705		
PET/CT vs. Stand-Alone PET.	707		
Clinical Indications of			
Perfusion Metabolism Imaging	708		
		17 Future Trends: Molecular PET	721
		17.1 Technical Potential and	
		Software Optimization	721
		17.2 Molecular PET	722
		Tumour Vitality and	
		Glucose Transporters (GLUT)	722
		Therapeutic and Diagnostic Potential	722
		17.3 Final Remark	723
		17.4 References	724
		Subject Index	727